<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818426</url>
  </required_header>
  <id_info>
    <org_study_id>UCPVax</org_study_id>
    <secondary_id>2015-001712-35</secondary_id>
    <nct_id>NCT02818426</nct_id>
  </id_info>
  <brief_title>Universal Cancer Peptide-based Vaccination in Metastatic NSCLC</brief_title>
  <acronym>UCPVax</acronym>
  <official_title>Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Invectys</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      UCPVAx is a therapeutic vaccine based on the telomerase-derived UCP designed to induce strong
      TH1 CD4 T cell responses in cancer patients.

      Three doses of UCPVax (0,25 mg, 0,5 mg and 1 mg) will be tested in this phase I/II study by
      using Continuous Reassessment Method (CRML) dose escalation design model.

      The phase I is a dose escalation study designed to evaluate safety of use of UCPVax and to
      estimate its Maximum Tolerated Dose (MTD).

      The phase II is a dose deescalation designed to evaluate the immunogenicity of UCPVax
      according to the dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UCPVax study is a prospective multicenter phase I/II study: 54 patients with metastatic NSCLC
      will be enrolled in 5 centers in France.

      A translational research program will be performed to better define the eligibility criteria
      and predictive biomarkers needed for randomized phase II and Phase III trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) of UCPVax (phase I)</measure>
    <time_frame>until day 57 after the first vaccination</time_frame>
    <description>The following adverse events graded according to CTCAE v 4.03 will be classified as DLTs :
Hematologic:
Grade 4 neutropenia (ANC &lt;0.5 x 109/L) lasting &gt;5 days;
Febrile neutropenia (defined as neutropenia ≥Grade 3 [ANC &lt;1000 cells/mm3] and a body temperature ≥38.5°C);
Grade ≥3 thrombocytopenia (&lt;50.0 - 25.0 x 109/L) with bleeding;
Grade 4 thrombocytopenia (&lt;25.0 x 109/L) &gt;5 days;
Grade 4 anemia (hemoglobin &lt;6.5 g/dL or 4.0 nmol/L);
Non-hematologic:
o Grade ≥3 toxicities, except for alopecia and those grade 3 events that respond to treatment (eg. grade 3 nausea, vomiting, diarrhea that responds to standard medical supportive care within 48 hours will not be considered a DLT).
Immune system disorder:
Grade ≥2 allergic reaction (except for local reaction at the injection site : grade ≥ 3)
Grade ≥2 autoimmune disease (colitis, thyroidis…)
Grade ≥2 cytokine release syndrome (nausea, headache, tachycardia, hypotension, rash and shortness of breath)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-related immunogenicity (phase II)</measure>
    <time_frame>at day 73</time_frame>
    <description>Antigen-specific T cell responses measured using IFN-gamma ELISPOT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>every 8 weeks up to 15 months</time_frame>
    <description>Tumor response evaluated per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>delay from the date of inclusion to the disease progression (RECIST) or death from any cause whichever occurs first,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>delay from the date of inclusion to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life (QoL)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>HrQoL will be assessed using EORTC QLQ-C30 and LC13 modules specific to lung cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events according to NCI CTCAE v.4.03</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>UCPVax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.
The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCPVax</intervention_name>
    <arm_group_label>UCPVax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell
             carcinoma, large cell carcinoma, undifferentiated carcinoma or other)

          -  Stage IIIB not amenable to radiotherapy or stage IV cancer according to the TNM
             classification (7th edition) or recurrent NSCLC after surgery not amenable to
             loco-regional therapy.

          -  Pre-treated with at least 2 or 3 lines of treatment (including immunotherapy).
             Chemoradiation for stage IIIB disease is considered as one treatment line.

          -  At least one measurable lesion by CT scan or MRI based on RECIST criteria version 1.1

          -  Performance status 0 or 1 on the ECOG scale

          -  Life-expectancy &gt; 3 months

          -  Adequate hematological, hepatic, and renal function

        Exclusion Criteria:

          -  Prior history of other malignancy except for: basal cell carcinoma of the skin,
             cervical intra-epithelial neoplasia and other cancer curatively treated with no
             evidence of disease for at least 5 years

          -  Symptomatic brain metastases. Patients with controlled brain metastases after
             radiation therapy or with asymptomatic brain metastases may be included.

          -  History of active autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel
             disease…)

          -  Patients under chronic treatment with systemic corticoids or other immunosuppressive
             drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) - - Positive serology for
             Human Immunodeficiency Virus (HIV) or Hepatitis C virus (HCV); presence in the serum
             of the antigens HBs

          -  Participation in a clinical study with an investigational product within 4 weeks prior
             to the start of the study treatment

          -  Pregnancy or lactating patients.

          -  Patients with any medical or psychiatric condition or disease,

          -  Patients under guardianship, curatorship or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier ADOTEVI, Pr</last_name>
    <phone>+33381668166</phone>
    <email>olivier.adotevi@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie WESTEEL, Pr</last_name>
    <email>virginie.westeel@univ-fcomte.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie WESTEEL, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno COUDERT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Foucher, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth FABRE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth QUOIX, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Galaine J, Borg C, Godet Y, Adotévi O. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel). 2015 Jun 30;3(3):490-502. doi: 10.3390/vaccines3030490. Review.</citation>
    <PMID>26350591</PMID>
  </reference>
  <reference>
    <citation>Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res. 2012 Nov 15;18(22):6284-95. doi: 10.1158/1078-0432.CCR-12-0896. Epub 2012 Oct 2.</citation>
    <PMID>23032748</PMID>
  </reference>
  <reference>
    <citation>Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012 May 15;18(10):2943-53. doi: 10.1158/1078-0432.CCR-11-3185. Epub 2012 Mar 8.</citation>
    <PMID>22407833</PMID>
  </reference>
  <reference>
    <citation>Godet Y, Dosset M, Borg C, Adotevi O. Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer? Oncoimmunology. 2012 Dec 1;1(9):1617-1619.</citation>
    <PMID>23264913</PMID>
  </reference>
  <reference>
    <citation>Adotévi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Hum Vaccin Immunother. 2013 May;9(5):1073-7. doi: 10.4161/hv.23587. Epub 2013 Jan 28. Review.</citation>
    <PMID>23357860</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer immunotherapy</keyword>
  <keyword>CD4 T lymphocyte helper</keyword>
  <keyword>telomerase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

